▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Exelixis (NASDAQ: EXEL)

$26.31

(3.1%)

$0.80

Price as of September 10, 2024, 4:00 p.m. ET

Exelixis Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
EXEL	+15.38%	+31.43%	+5.62%	+68%
S&P	+22.74%	+82.31%	+12.76%	+265%

Exelixis Company Info

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

News & Analysis

The Fool has written over 500 articles on Exelixis.

Featured Article

These Are Billionaires’ Favorite Healthcare Stocks

The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.

Jack Caporal | May 15, 2024

Featured Article

2 Stocks Under $30 to Buy and Hold

You don't need to be a millionaire to get started. Investing on a budget can work, too.

Prosper Junior Bakiny | Feb 19, 2024

Investing in Biotech ETFs

Keith Speights | Nov 9, 2023

Here are the five best biotech ETFs to invest in right now.

Is Exelixis Stock a Buy Now?

Prosper Junior Bakiny | Oct 18, 2023

There is one key reason to consider the stock.

2 Top Biotech Stocks Defying the Bear Market

Prosper Junior Bakiny | Sep 15, 2023

The best may be yet to come for these companies.

The Top Healthcare Stocks to Buy With $100

Prosper Junior Bakiny | Aug 30, 2023

Both stocks have outperformed the broader market in the last 12 months.

The Smartest Stocks to Buy With $20 Right Now and Hold Forever

Prosper Junior Bakiny | May 29, 2023

These companies can take investors on a lucrative ride, and all for the price of a few lattes.

2 Under-the-Radar Biotech Stocks to Buy in 2023

Prosper Junior Bakiny | May 24, 2023

Companies that don't make a lot of noise can still make you a lot of money.

Valuation

Podcast Episodes

Top Stocks That Are Already Crushing the Market in 2017

Exelixis, Pacira Pharmaceuticals, Kite Pharma, Exact Sciences, and Portola Pharmaceuticals are up more than 50% in the first two months of 2017.

Todd Campbell and Kristine Harjes | Mar 13, 2017

Earnings Transcripts

Exelixis (EXEL) Q2 2024 Earnings Call Transcript

EXEL earnings call for the period ending June 30, 2024.

Motley Fool Transcribing | Aug 7, 2024

Exelixis (EXEL) Q1 2024 Earnings Call Transcript

EXEL earnings call for the period ending March 31, 2024.

Motley Fool Transcribing | May 1, 2024

Exelixis (EXEL) Q4 2023 Earnings Call Transcript

EXEL earnings call for the period ending December 31, 2023.

Motley Fool Transcribing | Feb 6, 2024

Exelixis (EXEL) Q3 2023 Earnings Call Transcript

EXEL earnings call for the period ending September 30, 2023.

Motley Fool Transcribing | Nov 2, 2023

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services